AI Article Synopsis
- Fifty migraine patients underwent testing before and after a three-month treatment with flunarizine (10 mg per day) using a computerized telethermography device.
- Improvements were observed in 70% of the patients based on the telethermography results taken after treatment.
- The remaining patients did not show any significant changes in the telethermographic data.
Article Abstract
Fifty migraine patients were tested prior to and after a three-month period of flunarizine treatment (10 mg per day) by means of a new computerized telethermography apparatus. At completion of therapy a new computerized telethermography was carried out. The telethermographic data obtained showed an improvement in 70% of the cases; for the other patients telethermographic relevant modifications were not singled out.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/03331024850050S232 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Causal Association Between Obstructive Sleep Apnea and Migraine: A Bidirectional Mendelian Randomization Study.
Nat Sci Sleep
January 2025
Department of Stomatology, Gongli Hospital of Shanghai Pudong New Area, Shanghai, People's Republic of China.
Objective: Patients with obstructive sleep apnea (OSA) frequently suffer from migraine, however the causal relationship between OSA and migraine is unknown. Investigating the causation will assist in understanding the etiology of OSA and migraine.
Methods: Bidirectional two-sample Mendelian randomization (MR) and multivariable MR (MVMR) approaches were carried out to investigate the causal link between OSA and migraine.
Effect of long-term transcutaneous auricular vagus nerve stimulation in multiple system atrophy-cerebellar subtype: a case report.
Front Neurosci
January 2025
Department of Rehabilitation Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Background: Multiple system atrophy-cerebellar subtype (MSA-C) is a predominance of cerebellar ataxia and autonomic failure. MSA-C has a rapid progression, with average 9 years from symptom onset to death. Despite its prevalence, there is still a lack of effective treatments.
View Article and Find Full Text PDFAnxiety Disorders, Anxious Symptomology and Related Behaviors Associated With Migraine: A Narrative Review of Prevalence and Impact.
Curr Pain Headache Rep
January 2025
Department of Nursing, 2Nd Faculty of Medicine, Charles University, Prague, Czech Republic.
Purpose Of Review: The purpose of this study was to review the literature on the relationship between migraine, anxiety and related disorders, anxious symptomology and related behaviors.
Recent Findings: Generalized anxiety, other anxious disorders and migraine are comorbid. In addition, anxious symptomology and behaviors are common in people with migraine even if they do not meet diagnostic criteria or threshold.
Impact of CGRP monoclonal antibody treatment on blood pressure in patients with migraine: A systematic review and potential clinical implications.
Cephalalgia
January 2025
Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.
Background: Monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) or the CGRP-receptor have revolutionized the prevention of migraine. Despite their effectiveness, worries have surfaced regarding potential unwanted cardiovascular effects linked to the vasodilation function of CGRP, suggesting a potential influence on blood pressure (BP).
Methods: Studies were systematically retrieved from PubMed, Cochrane Database of Systematic Reviews, Web of Science, MEDLINE and EMBASE up to 1 May 2024.
Nanoformulation innovations: Revolutionizing precision in migraine therapy.
Iran J Basic Med Sci
January 2025
Departments of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Objectives: Migraine, a serious neurological disease that affects millions of people worldwide, is one of the most considerable burdens on the healthcare system and has significant economic implications. Even though various treatment methods are available, including medication, lifestyle changes, and behavioral therapy, many migraine sufferers do not receive adequate relief or experience intolerable side effects. Hence, the present review aims to evaluate the nanoformulation regarding migraine therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!